Update August 27th, 2019 – A must see video on (NASDAQ: INMB) https://www.youtube.com/watch?v=gLoNHjQUJMI
Update August 13th, 2019- INmune Bio Reports Second Quarter 2019 Financial Results and Provides Shareholder Update – https://finance.yahoo.com/news/inmune-bio-reports-second-quarter-130100786.html
August 5th, 2019 update – (NASDAQ: INMB) phase 1 data out this morning, click here- https://tradersnewssource.com/inmb-phase1-news/
This technology was only theoretical a few years ago and a concept with extraordinary potential.
Our human immune system is amazing.
Through a series of steps called the immune response, the immune system attacks organisms and substances that invade body systems and cause disease.
Sadly, our immune system isn’t designed to cure every disease that attacks our bodies. Diseases such as Alzheimer’s and Cancer aren’t included our body’s innate immune system design.
But what if our innate immune system could be reprogrammed to conquer even those insidious and sometimes deadly diseases.
What if our own bodies could fight Cancer and Alzheimer’s without having to subject ourselves to harsh therapeutic substances like chemo therapy.
Wouldn’t it be great if someone was working on that reprogramming of the natural immune system?
Well, someone is.
INmune Bio Inc. (NASDAQ: INMB) is a clinical stage biotechnology company that is developing new immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer and Alzheimer’s Disease (AD).
The INMB development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood; and XPro1595 for the treatment of Alzheimer’s disease.
Our bodies have two types of immunity:
Innate immunity refers to defense mechanisms that come into play immediately or within hours of an antigen’s appearance in the body. These mechanisms include physical barriers such as skin, chemicals in the blood, and immune system cells that attack foreign cells in the body. We are born with innate, or natural, immunity essentially made up of barriers to keep viruses, bacteria, parasites, and other foreign particles out of your body or limit their ability to spread.
Adaptive immunity refers to antigen-specific immune response. The adaptive immune response is more complex than the innate. The antigen first must be processed and recognized. Once an antigen has been recognized, the adaptive immune system creates an army of immune cells specifically designed to attack that antigen. For example, once you have measles you are immune from it forever, but not from other viruses such as mumps or chickenpox.
Most immune-oncology companies are working to develop therapies that work with the adaptive immunity system, but INmune is working with the innate immunity system utilizing a targeted biomarker response.
Let’s be clear about what INmune is working toward. They are developing compounds designed to reprogram our natural immune system to defeat cells beyond viruses, parasites and bacteria, such as cancer and Alzheimer’s. Think of the implications and potentials.
The company’s platforms target the overlooked elements of immunology:
• Innate immune system
• “Resistance” immunology of the Tumor Microenvironment
• Neuroinflammation is a cause of Alzheimer’s disease
We will talk more below about the clinical trials, and the company’s progress and potential. If you are reading this, you are likely an investor familiar with many biopharma and biotech clinical stage companies. You are probably familiar with companies that are working on therapies to treat cancer and Alzheimer’s with new drugs, but how many are working on therapies to bolster our own natural immune systems to treat the same diseases?
INmune is still under the radar of many investors as they just completed their IPO in February of 2019.
At the end of June, Dr. Mark Lowdell, Chief Scientific Officer and co-founder at INmune Bio, co-authored an article titled: “Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures,” summarizing the different effects between NK (natural killer) cell activation in response to tumor cells and cytokine-mediated activation.
The data cited in the article confirm that the primed NK cells generated by INB16 stimulation upregulate genes, which are crucial to NK-mediated killing of patients’ cancer cells.
Also, in June, R.J. Tesi, M.D., the company’s co-founder and CEO, presented at the Maxim Group’s conference on Alzheimer’s disease. During the conference, titled “Alzheimer’s Disease – What’s Next? Treating Alzheimer’s in a Post-Amyloid World,” Dr. Tesi discussed INmune Bio’s novel approach to treating Alzheimer’s with XPro1595, a second-generation selective inhibitor of soluble TNF (tumor necrosis factor) to combat neuroinflammation and microglial activation.
The graphic below discusses the immune system and the clinical trials for the INMB pipeline. More importantly to you, the investor, it highlights the upcoming potential catalysts associated with their products.
For those who want a more detailed, technical picture of the INMB products, how they work and what data has been generated from studies and clinical trials; we have provided the link below to a full presentation: https://www.inmunebio.com/images/INMB_non-con.June2019.v22.214.171.124.pdf
In order to advance XPro1595 in the treatment of AD, INmune was recently awarded a $1 million grant from the Alzheimer’s Association.
The grant will support a biomarker-directed Phase 1 clinical trial in 18 patients with mild-to-moderate AD. XPro1595 will be administered subcutaneously once a week for three months and biomarkers of inflammation will be assessed at 0, 6, and 12 weeks.
Market potential for the INMB product pipeline:
• XPro1595 – Alzheimer’s/dementia market
5.8 M patients in US
2019 estimated cost to care for US AD patients $280 billion
• INKmune – Cancer residual disease market
1,735,350 new cases and 609,640 people will die
Initial targets: Ovarian Cancer and High Risk MDS
• INB03 – Resistance to Checkpoint Inhibitors market
CPI’s work 27% of patients. CPI 2025 estimated market size $56 billion
INB03 in combination with CPI’s should increase the number of patients sensitive to CPIs.
Initial targets: Melanoma and Renal Cell Cancer
Would you be surprised to hear that insiders have spent $770,000 buying up company shares in the past two months and they own 63% of the outstanding shares?
The public float is only 2.98 million shares
INmune has no debt
Date Brokerage Action Rating Price Target
6/10/2019 Maxim Group Set Target Buy $13.00
Can the work being done at INMB be successful enough to bring to market? Preliminary data shows that success is possible. Upcoming clinical trials will define the future for INmune and any positive data from those clinical trials could be strong catalysts for the company’s value. Today they are working toward immunity from Alzheimer’s and certain oncology indications. Who knows where success against those diseases could lead the company?
The work being done at INMB is not only important to the advancement of good health in humans, the market potential for the company’s product pipeline is very attractive. INMB seems like it could be a ground floor investment opportunity in cutting edge medical technology.
Stay tuned for more on INMB coming soon,
The Traders News Group
TradersNewsSource.com collects your contact information to keep you informed about updates to our web site, newsletters and social channels. All information is kept secure, with only authorized employees having access.
TradersNewsSource.com does from time to time, issue releases to subscribers as “Feature Reports” that may be related to our content partners or advertising sponsors.
We do not sell your contact information to other organizations for commercial purposes. We will not release your email address to anyone, unless you specifically give us permission to do so. Should you decide in the future to unsubscribe from TradersNewsSource.com at any time, simply follow the instructions located at the bottom of each newsletter edition. Your email address will be kept strictly confidential, and will never be shared with anyone for any purpose of any kind.
Regarding Google ads:
ALL STOCKS INVOLVE RISKS AND THE POSSIBILITY OF LOSING ALL OF YOUR INVESTMENT. PLEASE CONSIDER ALL RISKS BEFORE INVESTING.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. TNS LLC has been compensated fifty thousand dollars cash via bank wire by worldwide holdings, DBA Invictus resources for awareness of INMB including this report. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.